Abstract: Provides herein are compositions for the treatment of chronic vulval or perineal pain, and of symptoms or conditions associated therewith, comprising an estrogen, optionally estriol, and a tricyclic antidepressant, optionally amitriptyline, formulated for topical, transdermal or transmucosal administration. Also provided are methods for the production of said compositions and to uses thereof in the treatment of chronic vulval or perineal pain, and of symptoms or conditions associated therewith.

Abstract: According to the invention there is provided a compound of Formula (I) in which: A is a C2-8 alkylene group; R1, R2, R3, and R4 are independently selected from hydrogen, C1-4 alkyl, C2-4 dihydroxyalkyl in which the carbon atom attached to the nitrogen atom does not carry a hydroxyl group and no carbon atom is substituted by two hydroxyl groups, or R2 and R3 together form a C2-6 alkylene group which with the nitrogen atom to which R2 and R3 are attached forms a heterocyclic ring; X1, X2 and X3 are independently selected from hydrogen, hydroxyl, NR1-A-NR2R3R4+(Zm?)1/m, for halogeno amino, C1-4 alkoxy or C2-8 alkanoyloxy; and (Zm?)1/m is an anion of charge m; or a derivative in which the group NR1 is quaternarized.

Abstract: This invention relates to a 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula (I) and crystalline solid forms and compositions thereof. Also disclosed herein are methods of making crystalline solid forms of the 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula (I) and methods of using the 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula (I) or crystalline solid forms, pharmaceutically acceptable salts, and pharmaceutically acceptable compositions thereof.

Abstract: The present invention relates to a pharmaceutical combination comprising a first active ingredient which is N-[1-(5-Cyano-pyridin-2-ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide or a pharmaceutically acceptable salt thereof and a second active ingredient which has an anti-epileptic effect, or a pharmaceutically acceptable salt thereof.

Abstract: The present invention refers to a new enzymatic process for obtaining 17?-monoesters of cortexolone and/or its 9,11-dehydroderivatives starting from the corresponding 17?,21-diesters which comprises an enzymatic alcoholysis reaction. Furthermore, the present invention refers to new crystalline forms of cortexolone-17?-propionate and 9,11-dehydro-cortexolone 17?-butanoate.

Abstract: Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties.

Abstract: The tetracycline class of antibiotics has played a major role in the treatment of infectious diseases for the past 50 years. However, the increased use of the tetracyclines in human and veterinary medicine has led to resistance among many organisms previously susceptible to tetracycline antibiotics. The modular synthesis of tetracyclines and tetracycline analogs described provides an efficient and enantioselective route to a variety of tetracycline analogs and polycyclines previously inaccessible via earlier tetracycline syntheses and semi-synthetic methods. These analogs may be used as anti-microbial agents or anti-proliferative agents in the treatment of diseases of humans or other animals.

Abstract: A compound with antibacterial activity having the following formula (I): is disclosed. A method of preparing the compound of formula (I) is also disclosed.

Abstract: The present invention relates to the technical field of herbicide crystallization process, particularly to Crystalline form C of shuangzuocaotong, and a preparation method therefor and use thereof. The Crystalline form C of shuangzuocaotong has an X-ray powder diffraction pattern having characteristic absorption peaks at the following 2? positions: 10.159, 10.658, 13.318, 14.579, 16.096, 18.061, 19.322, 19.68, 20.04, 20.659, 21.281, 23, 24.16, 24.619, 26.101, 26.74, 30.359, 31.018, 32.378, 35.398 and 38.26 degrees, wherein 2? has an error range within ±0.2°. The Crystalline form C of shuangzuocaotong has good stability, and its compounded composition with additional active ingredient(s) has a good control effect to broadleaf weeds and some gramineous weeds in wheat, significantly better than that of Crystalline form A of shuangzuocaotong.

Abstract: The present invention provides a composition for adjusting biological tissue size and a method for adjusting the size of biological tissue using the said composition. The composition for adjusting the size of biological tissue according to the present invention can adjust the size of biological tissue according to the specifications of a microscope and the needs of a researcher, and can be used as a mounting solution to easily acquire an image of the biological tissue. Therefore, the composition can be usefully used to reveal the causes of and find treatment methods for various disorders.

Abstract: Described herein are neuroactive steroids of the Formula (I): or a pharmaceutically acceptable salt thereof; wherein , A, R1, R2, and R3 are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use, e.g., for treating a subject suffering from a disease or disorder described herein.

Abstract: Certain embodiments are directed to methods and compositions for preventing or treating bacterial infections. In certain embodiments the compositions comprise thioredoxin inhibitors, and/or thioredoxin-like inhibitors.

Abstract: Testosterone ester triglyceride formulations, optionally further including adducts. Methods of in-situ control of the manufacture or formation of such adducts are also described.

Abstract: The present invention relates generally to the compound: N-((4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,12a,14,14a,14b-octadecahydropicen-4a-yl)-2,2-difluoropropanamide, polymorphic forms thereof, methods for preparation and use thereof, pharmaceutical compositions thereof, and kits and articles of manufacture thereof.

Abstract: Compounds are provided according to Formula (I) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, and R3 are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.

Abstract: Compositions including a complex of fatty acids (e.g., including one or more C4 to C40 fatty acids, such as a C4 to C20 fatty acid) and one or more amino acids (and particularly one or more amino acids having electrically charged basic side chains, e.g., Arginine, Lysine, etc.) for use as an anti-pathogenic composition. These compositions may include the complex of fatty acid:amino acid having a lamellar supramolecular structure. In particular, described herein are therapeutic compositions of undecylenic acid:Arginine forming a complex of undecylenic acid and Arginine.

Abstract: Compounds are provided according to Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3a, R3b, R4, R5a, R5b, R6a, and R6b are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of CNS-related conditions.

Abstract: The present invention is an aqueous solution which contains two types of methyl celluloses, polyethylene glycol, polyvinylpyrrolidone, and citric acid or a pharmaceutically acceptable salt thereof. The composition of the present invention maintains a low viscosity around room temperature, but the composition is suddenly increased in the viscosity due to heat around the body temperature and has thixotropy even after gelation.

Abstract: The present invention relates to solid forms of (S)—N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide and process for producing the same.

Abstract: An ophthalmic composition containing sulfasalazine and hyaluronic acid is disclosed.